Premium
Isoprostanes, a novel markers of oxidative stress in schizophrenic disorders
Author(s) -
DietrichMuszalska A.,
Olas B.,
Wachowicz B.
Publication year - 2003
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1046/j.1471-4159.85.s2.19_9.x
Subject(s) - oxidative stress , isoprostane , isoprostanes , schizophrenia (object oriented programming) , olanzapine , arachidonic acid , antipsychotic , quetiapine , lipid peroxidation , urine , medicine , prostaglandin , chemistry , endocrinology , psychiatry , biochemistry , enzyme
Molecular processes including oxidative stress play an important role in pathology of schizophrenia. Isoprostanes are a family of novel prostaglandin isomers and are produced in a free radical catalyzed reactions from arachidonic acid and they are useful as a specific, chemically stable, noninvasive index of free radical generation in vivo . We therefore assessed the level of urinary excretion of 8‐epi‐prostaglandin F 2 ‐marker of lipid peroxidation using an immunoassay kit (Oxis International, Inc.) in urine from schizophrenia and control subjects. According to DSM‐IV criteria all patients had diagnosis of paranoid type. All patients were treated with antipsychotic drugs of II generation (risperidone, quetiapine, olanzapine). Mean time of schizophrenia duration was 4 years. We observed an increased level of isoprostane in urine of schizophrenic patients in comparison with a control group. Our preliminary results support a role of oxidative stress in schizophrenic disorders.